EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Alimera Sciences's enterprise value is $226.55 Mil.
Alimera Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $80.75 Mil. Therefore, Alimera Sciences's EV-to-Revenue for today is 2.81.
The historical rank and industry rank for Alimera Sciences's EV-to-Revenue or its related term are showing as below:
ALIM'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.9 Med: 3.18 Max: 931.8
Current: 2.81
During the past 13 years, the highest EV-to-Revenue of Alimera Sciences was 931.80. The lowest was 0.90. And the median was 3.18.
ALIM's EV-to-Revenue is ranked worse than 61.25% of 1027
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs ALIM: 2.81
As of today (2024-04-26), Alimera Sciences's stock price is $3.452.
Alimera Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $5.32. Therefore, Alimera Sciences's PS Ratio for today is 0.65.
Alimera Sciences EV-to-Revenue Historical Data
The historical data trend for Alimera Sciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alimera Sciences's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alimera Sciences's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Alimera Sciences's EV-to-Revenue falls into.
Alimera Sciences's current Enterprise Value is $226.55 Mil.
Alimera Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $80.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alimera Sciences's share price for today is $3.452.
Alimera Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.32.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alimera Sciences EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Alimera Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Alimera Sciences (Alimera Sciences) Business Description
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALIM has been successfully added to your 